The Top 5 Biosimilars Articles for the Week of June 22

Here are the top 5 biosimilars articles for the week of June 22, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of June 22, 2020.

Number 5: Plaintiffs in a novel class-action lawsuit against AbbVie have until the end of June to try again to pursue their claims that the maker of the originator adalimumab (Humira) created a patent thicket that makes it nearly impossible for rivals to gain a foothold.

Number 4: Shanghai Henlius Biotech said a trial of its bevacizumab biosimilar candidate HLX04 met its primary end point of progression-free survival at 9 months in patients with metastatic colorectal cancer.

Number 3: A joint position statement on biosimilars for the treatment of inflammatory bowel disease sparked backlash and criticism over the recommendation against nonmedical switching from reference infliximab to a biosimilar.

Number 2: Studies on switching and retention for adalimumab and etanercept biosimilars yielded positive data, according to abstracts presented at the EULAR 2020 Congress, the virtual meeting of the European League Against Rheumatism.

Number 1: Eli Lilly gets FDA approval for a new formulation of insulin lispro and offers it at the out-of-pocket cap of $35 for a monthly supply for patients with or without insurance.

To read all of these articles and more, visit